Wave Life Sciences Reports Positive WVE-007 Obesity Trial Data

Wave Life Sciences ( (WVE) ) just unveiled an announcement.

On March 26, 2026, Wave Life Sciences reported positive interim Phase 1 data from its first-in-human INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA, in otherwise healthy individuals with overweight or obesity. A single 240 mg dose showed significant placebo-adjusted reductions in visceral fat and total fat, stabilization of lean mass, and reductions in waist circumference and body weight over six months, with durable Activin E suppression supporting once or twice-yearly dosing.

The company highlighted that improvements in body composition, particularly visceral fat-to-muscle ratio, exceeded those seen with weekly semaglutide in a higher-BMI population, while WVE-007 remained generally safe and well tolerated up to 600 mg. Wave plans to initiate a Phase 2a multidose INLIGHT study in the second quarter of 2026 in individuals with higher BMI and comorbidities to further assess body composition, weight loss, and cardiometabolic markers, informing development in obesity, MASH, type 2 diabetes, and cardiovascular disease.

The most recent analyst rating on (WVE) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Spark’s Take on WVE Stock

According to Spark, TipRanks’ AI Analyst, WVE is a Neutral.

The score is held back primarily by weak financial performance (steep revenue decline, large losses, and heavy cash burn). Offsetting this, the latest earnings call points to strong clinical/program momentum and a runway into Q3 2028, while technical signals are moderately supportive and valuation remains constrained by negative earnings.

To see Spark’s full report on WVE stock, click here.

More about Wave Life Sciences

Wave Life Sciences Ltd. is a Cambridge, Mass.-based clinical-stage biotechnology company focused on developing RNA medicines, including GalNAc-siRNA therapeutics, aimed at transforming treatment of cardiometabolic and other chronic diseases. The company targets genetically validated pathways such as INHBE/Activin E to address obesity and related conditions including MASH, type 2 diabetes, and cardiovascular disease.

Average Trading Volume: 3,290,810

Technical Sentiment Signal: Buy

Current Market Cap: $2.32B

See more data about WVE stock on TipRanks’ Stock Analysis page.